EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|July 1, 2004
Master of pediatrics III
In a continuing series from Dermatology Times, a panel of pediatric masters discusses treatment options for specific and unusual cases. This third case is that of a 15-month-old male brought in by his mother for management of perianal warts. What are the various treatment options for the child?
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
4
Repigmentation With Upadacitinib Continues Through Week 76 in Non-Segmental Vitiligo
5